The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The party leader said her MPs may be in a position to act as deal makers - and they would refuse to allow an exit from the EU.
Oliver Healey said he set up the page before the referendum and it has now been "hijacked" by Remain backers.
Another unsettled day ahead for most.